CA
NZ
UK
AU
IND
US
Danaher (NYSE:DHR) is trading lower in Thursday's session as Julie Sawyer Montgomery formally assumed the roles of President and CEO of the life sciences and diagnostics company and joined its board. The shares are down 3.51% at $213.77 and underperforming a healthcare sector that …
Foghorn Therapeutics (NASDAQ:FHTX), a penny stock trading near $2.84, is falling sharply in Thursday's session after announcing it has stopped developing FHD-909, an experimental cancer drug partnered with Eli Lilly (NYSE:LLY). The Watertown, Massachusetts-based biotech develops medicines that target the chromatin regulatory system, and …
Johnson & Johnson (NYSE:JNJ) is pulling back in Thursday's session, giving up ground after a run that lifted the shares roughly 43% over the past year to levels near record highs. The stock is trading around $259, down 2.00%, against a 52-week high of …
Eli Lilly (NYSE:LLY) is slipping in Thursday's session even as the drugmaker stacked up fresh evidence for Foundayo, its once-daily oral GLP-1 pill. Shares are changing hands near $1,146, down 0.95%, in a market where healthcare stocks are lagging andWall Streethas opened the fourth …
Liquidia (NASDAQ:LQDA) is falling again in Thursday's session after a Delaware federal court ruled in favor of United Therapeutics (NASDAQ:UTHR) in a patent case over Yutrepia, its inhaled treprostinil powder. The shares are down about 11% at $26.96, following a drop of roughly 57% …
Nanobiotix (NASDAQ:NBTX) is sliding in Thursday's session following its first-half 2026 update, which showed revenue and other income falling to €5.6 million from €26.6 million and a net loss of €34.3 million. The Paris-based late-stage biotech develops NBTXR3, a first-in-class radioenhancer made of hafnium …
Nektar Therapeutics (NASDAQ:NKTR) is sliding sharply in Thursday's session even though the San Francisco-based clinical-stage biotech presented encouraging long-term data for its lead candidate, rezpegaldesleukin, a regulatory T cell-stimulating therapy. The shares are down about 20% at $48.67 on volume far above the recent …
Nexalin Technology (NASDAQ:NXL) is soaring in Thursday's session after announcing a definitive distribution agreement for its Nexalin Sync neurostimulation device, which has Brazilian regulatory approval for anxiety, depression and insomnia. The Houston-based medical device company develops non-invasive deep brain stimulation technology for mental health …
Surgery Partners (NASDAQ:SGRY) is moving lower in Thursday's session as investors weigh its Idaho Falls divestiture against a stretched share price and a backdrop of rising yields. The Brentwood, Tennessee-based company, majority-owned by Bain Capital, operates a nationwide network of more than 200 short-stay …
SELLAS Life Sciences (NASDAQ:SLS) is trading lower in Thursday's session with no new company news, as investors sit in a holding pattern ahead of a pivotal readout. The New York-based late-stage biotech is developing galinpepimut-S, a peptide immunotherapy targeting the Wilms tumor 1 protein, …
Please wait processing your request...